Broadening horizons: ferroptosis as a new target for traumatic brain injury

Ziqing Wei; Haihan Yu; Huijuan Zhao; Mingze Wei; Han Xing; Jinyan Pei; Yang Yang; Kaidi Ren

doi:10.1093/burnst/tkad051

您当前的位置：

首页 >

文章列表页 >

Broadening horizons: ferroptosis as a new target for traumatic brain injury

更新时间：2024-04-19

- Broadening horizons: ferroptosis as a new target for traumatic brain injury
- Broadening horizons: ferroptosis as a new target for traumatic brain injury
- Burns & Trauma 2024年12卷第1期
- 作者机构：
  
  1. Department of Neurology, The First Affiliated Hospital of Zhengzhou University
  2. Henan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University
  3. Clinical Systems Biology Laboratories, The First Affiliated Hospital of Zhengzhou University
  4. Henan International Joint Laboratory of Thrombosis and Hemostasis
  5. Henan University of Science and Technology
  6. The Second Clinical Medical College, Harbin Medical University
  7. Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University
  8. Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University
  9. Quality Management Department
  10. Clinical Systems Biology Research Laboratories
  11. the First Affiliated Hospital of Zhengzhou University
- 作者简介：
- 基金信息：
  
  This work was supported by the National Natural Science Foundation of China (No. 82204389, No. 82301342, and No. 82201455) and the Henan Medical Science and Technique Foundation (No. LHGJ20210351).
- DOI：10.1093/burnst/tkad051
  中图分类号：
- 纸质出版日期：2024，
  
  网络出版日期：2024-1-18，
扫描看全文
Ziqing Wei, Haihan Yu, Huijuan Zhao, 等. Broadening horizons: ferroptosis as a new target for traumatic brain injury[J]. Burns & Trauma, 2024,12(1).

Ziqing Wei, Haihan Yu, Huijuan Zhao, Mingze Wei, Han Xing, Jinyan Pei, Yang Yang, Kaidi Ren, Broadening horizons: ferroptosis as a new target for traumatic brain injury, Burns & Trauma, Volume 12, 2024, tkad051, https://doi.org/10.1093/burnst/tkad051
Ziqing Wei, Haihan Yu, Huijuan Zhao, 等. Broadening horizons: ferroptosis as a new target for traumatic brain injury[J]. Burns & Trauma, 2024,12(1). DOI： 10.1093/burnst/tkad051.

Ziqing Wei, Haihan Yu, Huijuan Zhao, Mingze Wei, Han Xing, Jinyan Pei, Yang Yang, Kaidi Ren, Broadening horizons: ferroptosis as a new target for traumatic brain injury, Burns & Trauma, Volume 12, 2024, tkad051, https://doi.org/10.1093/burnst/tkad051 DOI：

摘要

Abstract

Traumatic brain injury (TBI) is a leading cause of death and disability worldwide

with ~50 million people experiencing TBI each year. Ferroptosis

a form of regulated cell death triggered by iron ion-catalyzed and reactive oxygen species-induced lipid peroxidation

has been identified as a potential contributor to traumatic central nervous system conditions

suggesting its involvement in the pathogenesis of TBI. Alterations in iron metabolism play a crucial role in secondary injury following TBI. This study aimed to explore the role of ferroptosis in TBI

focusing on iron metabolism disorders

lipid metabolism disorders and the regulatory axis of system Xc−/glutathione/glutathione peroxidase 4 in TBI. Additionally

we examined the involvement of ferroptosis in the chronic TBI stage. Based on these findings

we discuss potential therapeutic interventions targeting ferroptosis after TBI. In conclusion

this review provides novel insights into the pathology of TBI and proposes potential therapeutic targets.

关键词

Keywords

Traumatic brain injuryFerroptosisTherapeutic targetsLipid peroxidationReactive oxygen speciesMetabolismBlood-brain barrier

references

1.Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017;16:987–1048.

2.Salottolo K, Carrick M, Stewart Levy A, Morgan BC, Slone DS, Bar-Or D. The epidemiology, prognosis, and trends of severe traumatic brain injury with presenting Glasgow coma scale of 3. J Crit Care. 2017;38:197–201.

3.Shi H, Hua X, Kong D, Stein D, Hua F. Role of toll-like receptor mediated signaling in traumatic brain injury. Neuropharmacology. 2019;145:259–67.

4.Zhao ZA, Yan L, Wen J, Satyanarayanan SK, Yu F, Lu J, et al. Cellular and molecular mechanisms in vascular repair after traumatic brain injury: a narrative review. Burns. Trauma. 2023;11:tkad033.

5.Wang TY, Park C, Zhang H, Rahimpour S, Murphy KR, Goodwin CR, et al. Management of Acute Traumatic Spinal Cord Injury: a review of the literature. Front Surg. 2021;8:698736.

6.Schwartz G, Fehlings MG. Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177–90.

7.Rath N, Balain B. Spinal cord injury-the role of surgical treatment for neurological improvement. J Clin Orthop Trauma. 2017;8:99–102.

8.Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.

9.Shen L, Lin D, Li X, Wu H, Lenahan C, Pan Y, et al. Ferroptosis in acute central nervous system injuries: the future direction? Front Cell Dev Biol. 2020;8:594.

10.Xiao X, Jiang Y, Liang W, Wang Y, Cao S, Yan H, et al. miR-212-5p attenuates ferroptotic neuronal death after traumatic brain injury by targeting Ptgs2. Mol Brain, 2019, 12: 78.

11.Vitalakumar D, Sharma A, Flora SJS. Ferroptosis: a potential therapeutic target for neurodegenerative diseases. J Biochem Mol Toxicol. 2021;35:e22830.

12.Zhang C, Rodriguez C, Spaulding J, Aw TY, Feng J. Age-dependent and tissue-related glutathione redox status in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2012;28:655–66.

13.Zhang Y, Yang S, Liu C, Han X, Gu X, Zhou S. Deciphering glial scar after spinal cord injury. Burns. Trauma. 2021;9:tkab035.

14.Wang Y, Wei Z, Pan K, Li J, Chen Q. The function and mechanism of ferroptosis in cancer. Apoptosis. 2020;25:786–98.

15.Kim SE, Zhang L, Ma K, Riegman M, Chen F, Ingold I, et al. . Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumor growth. Nat Nanotechnol, 2016, 11: 977–85.

16.Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273–85.

17.Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17:2054–81.

18.Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci. 2014;19:164–74.

19.Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15:234–45.

20.Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721–41.

21.He YJ, Liu XY, Xing L, Wan X, Chang X, Jiang HL. Fenton reaction-independent ferroptosis therapy via glutathione and iron redox couple sequentially triggered lipid peroxide generator. Biomaterials. 2020;241:119911.

22.Gaschler MM, Stockwell BR. Lipid peroxidation in cell death. Biochem Biophys Res Commun. 2017;482:419–25.

23.Xie BS, Wang YQ, Lin Y, Mao Q, Feng JF, Gao GY, et al. Inhibition of ferroptosis attenuates tissue damage and improves long-term outcomes after traumatic brain injury in mice. CNS Neurosci Ther. 2019;25:465–75.

24.Huang S, Li S, Feng H, Chen Y. Iron metabolism disorders for cognitive dysfunction after mild traumatic brain injury. Front Neurosci. 2021;15:587197.

25.Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, et al., PEBP1 wardens Ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell, 2017, 171: 628–641.e26.

26.Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81–90.

27.Lee JY, Kim WK, Bae KH, Lee SC, Lee EW. Lipid metabolism and Ferroptosis. Biology (Basel). 2021;10. https://doi.org/10.3390/biology10030184.

28.Küch EM, Vellaramkalayil R, Zhang I, Lehnen D, Brügger B, Sreemmel W, et al. Differentially localized acyl-CoA synthetase 4 isoenzymes mediate the metabolic channeling of fatty acids toward phosphatidylinositol. Biochim Biophys Acta. 2014;1841:227–39.

29.Hishikawa D, Shindou H, Kobayashi S, Nakanishi H, Taguchi R, Shimizu T. Discovery of a lysophospholipid acyltransferase family essential for membrane asymmetry and diversity. Proc Natl Acad Sci U S A. 2008;105:2830–5.

30.Imig JD, Khan MA. Cytochrome P450 and lipoxygenase metabolites on renal function. Compr Physiol. 2015;6:423–41.

31.Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A. 2016;113:E4966–75.

32.Yan B, Ai Y, Sun Q, Ma Y, Cao Y, Wang J, et al. Membrane damage during Ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Mol Cell. 2021;81:355–369.e10.

33.Hogan SR, Phan JH, Alvarado-Velez M, Wang MD, Bellamkonda RV, Fernández FM, et al. Discovery of Lipidome alterations following traumatic brain injury via high-resolution metabolomics. J Proteome Res. 2018;17:2131–43.

34.Kenny EM, Fidan E, Yang Q, Anthonymuthu TS, New LA, Meyer EA, et al. Ferroptosis contributes to neuronal death and functional outcome after traumatic brain injury. Crit Care Med. 2019;47:410–8.

35.Li Q, Han X, Lan X, Gao Y, Wan J, Durham F, et al. Inhibition of neuronal ferroptosis protects hemorrhagic brain. JCI Insight. 2017;2:e90777. https://doi.org/10.1172/jci.insight.90777.

36.Bridges RJ, Natale NR, Patel SA. System xc(−) cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol. 2012;165:20–34.

37.Broer S, Wagner CA. Structure–function relationships of heterodimeric amino acid transporters. Cell Biochem Biophys. 2002;36:155–68.

38.Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y. CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Arch. 2004;447:532–42.

39.Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumor suppression. Nature, 2015, 520: 57–62.

40.Zhang X, Sui S, Wang L, Li H, Zhang L, Xu S, et al. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. J Cell Physiol. 2020;235:3425–37.

41.Zhang Y, Lan J, Zhao D, Ruan C, Zhou J, Tan H, et al. Netrin-1 upregulates GPX4 and prevents ferroptosis after traumatic brain injury via the UNC5B/Nrf2 signaling pathway. CNS Neurosci Ther. 2023;29:216–27.

42.Wang HC, Lin YJ, Shih FY, Chang HW, Su YJ, Cheng BC, et al. The role of serial oxidative stress levels in acute traumatic brain injury and as predictors of outcome. World Neurosurg. 2016;87:463–70.

43.Yu H, Guo P, Xie X, Wang Y, Chen G. Ferroptosis, a new form of cell death, and its relationships with tumorous diseases. J Cell Mol Med. 2017;21:648–57.

44.Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigó R, et al. Characterization of mammalian selenoproteomes. Science. 2003;300:1439–43.

45.Warner GJ, Berry MJ, Moustafa ME, Carlson BA, Hatfield DL, Faust JR. Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]sec lacking isopentenyladenosine. J Biol Chem. 2000;275:28110–9.

46.Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26:165–76.

47.Alim I, Caulfield JT, Chen Y, Swarup V, Geschwind DH, Ivanova E, et al. Cell. 2019;177:1262–1279.e25.

48.Chen J, Zhang X, Li L, Ma X, Yang C, Liu Z, et al. Farnesyl pyrophosphate is a new danger signal inducing acute cell death. PLoS Biol. 2021;19:e3001134.

49.Xia Y, Xie Y, Yu Z, Xiao H, Jiang G, Zhou X, et al. The mevalonate pathway is a Druggable target for vaccine adjuvant discovery. Cell. 2018;175:1059–1073.e21.

50.Zheng J, Conrad M. The metabolic underpinnings of Ferroptosis. Cell Metab. 2020;32:920–37.

51.Bentinger M, Tekle M, Dallner G. Coenzyme Q--biosynthesis and functions. Biochem Biophys Res Commun. 2010;396:74–9.

52.Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693–8.

53.Ashidate K, Kawamura M, Mimura D, Tohda H, Miyazaki S, Teramoto T, et al. Gentisic acid, an aspirin metabolite, inhibits oxidation of low-density lipoprotein and the formation of cholesterol ester hydroperoxides in human plasma. Eur J Pharmacol, 2005, 513: 173–9.

54.Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688–92.

55.Tang S, Gao P, Chen H, Zhou X, Ou Y, He Y. The role of iron, its metabolism and Ferroptosis in traumatic brain injury. Front Cell Neurosci. 2020;14:590789.

56.Wu AG, Yong YY, Pan YR, Zhang L, Wu JM, Zhang Y, et al. Targeting Nrf2-mediated oxidative stress response in traumatic brain injury: therapeutic perspectives of phytochemicals. Oxidative Med Cell Longev. 2022;2022:1–24.

57.Bryan HK, Olayanju A, Goldring CE, Park BK. The Nrf2 cell defense pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol. 2013;85:705–17.

58.Katoh Y, Iida K, Kang M I, Kobayashi A, Mizukami M, Tong K I, et al. Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. Arch Biochem Biophys, 2005, 433: 342–50.

59.Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol. 2004;24:10941–53.

60.Wang H, Zhou XM, Wu LY, Liu GJ, Xu WD, Zhang XS, et al. Aucubin alleviates oxidative stress and inflammation via Nrf2-mediated signaling activity in experimental traumatic brain injury. J Neuroinflammation. 2020;17:188.

61.Cheng H, Wang P, Wang N, Dong W, Chen Z, Wu M, et al. Neuroprotection of NRF2 against Ferroptosis after traumatic brain injury in mice. Antioxidants (Basel). 2023;12. https://doi.org/10.3390/antiox12030731.

62.Gao P, Zhou M, Ouyang Y, Wang H. Activation of the nuclear factor erythroid 2-related factor 2-antioxidant response element signal in rats with diffuse axonal injury. Neuroreport. 2019;30:389–96.

63.Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015;125:25–32.

64.Xu F, Na L, Li Y, Chen L. Roles of the PI3K/AKT/mTOR signaling pathways in neurodegenerative diseases and tumors. Cell Biosci. 2020;10:54.

65.Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci U S A. 2020;117:31189–97.

66.Baba Y, Higa JK, Shimada BK, Horiuchi KM, Suhara T, Kobayashi M, et al. Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2018;314:H659–68.

67.Zhang Y, Swanda RV, Nie L, Liu X, Wang C, Lee H, et al. mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nat Commun, 2021, 12: 1589.

68.Movahedpour A, Vakili O, Khalifeh M, Mousavi P, Mahmoodzadeh A, Taheri-Anganeh M, et al. Mammalian target of rapamycin (mTOR) signaling pathway and traumatic brain injury: a novel insight into targeted therapy. Cell Biochem Funct. 2022;40:232–47.

69.Kim SY, Buckwalter M, Soreq H, Vezzani A, Kaufer D. Blood–brain barrier dysfunction-induced inflammatory signaling in brain pathology and epileptogenesis. Epilepsia. 2012;53 Suppl 6:37–44.

70.Citraro R, Leo A, Constanti A, Russo E, De Sarro G. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol Res. 2016;107:333–43.

71.Sbodio JI, Snyder SH, Paul BD. Regulators of the transsulfuration pathway. Br J Pharmacol. 2019;176:583–93.

72.Liu M, Kong XY, Yao Y, Wang XA, Yang W, Wu H, et al. The critical role and molecular mechanisms of ferroptosis in antioxidant systems: a narrative review. Ann Transl Med. 2022;10:368.

73.Hayano M, Yang WS, Corn CK, Pagano NC, Stockwell BR. Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ. 2016;23:270–8.

74.Tchantchou F, Miller C, Goodfellow M, Puche A, Fiskum G. Hypobaria-induced oxidative stress facilitates homocysteine Transsulfuration and promotes glutathione oxidation in rats with mild traumatic brain injury. J Cent Nerv Syst Dis. 2021;13:1179573520988193.

75.Chen X, Kang R, Kroemer G, Tang D. Organelle-specific regulation of ferroptosis. Cell Death Differ. 2021;28:2843–56.

76.Picard M, Shirihai OS. Mitochondrial signal transduction. Cell Metab. 2022;34:1620–53.

77.Gao M, Yi J, Zhu J, Minikes AM, Monian P, Thompson CB, et al. Role of mitochondria in Ferroptosis. Mol Cell. 2019;73:354–363.e3.

78.Bebber CM, Muller F, Prieto Clemente L, Weber J, Von Karstedt S. Ferroptosis in cancer cell biology. Cancers (Basel). 2020;12:1.

79.Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369–79.

80.Schwarz DS, Blower MD. The endoplasmic reticulum: structure, function and response to cellular signaling. Cell Mol Life Sci. 2016;73:79–94.

81.Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta. 2013;1833:3460–70.

82.He F, Zhang P, Liu J, Wang R, Kaufman RJ, Yaden BC, et al. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. J Hepatol. 2023;79:362–77.

83.Chen MS, Wang SF, Hsu CY, Yin PH, Yeh TS, Lee HC, et al. CHAC1 degradation of glutathione enhances cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-eIF2alpha-ATF4 pathway. Oncotarget. 2017;8:114588–602.

84.Alborzinia H, Ignashkova TI, Dejure FR, Gendarme M, Theobald J, Wölfl S, et al. Golgi stress mediates redox imbalance and ferroptosis in human cells. Commun Biol. 2018;1:210.

85.Zhang Z, Yue P, Lu T, Wang Y, Wei Y, Wei X. Role of lysosomes in physiological activities, diseases, and therapy. J Hematol Oncol. 2021;14:79.

86.Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4:151–75.

87.Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ, 3rd, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016;12:1425–8.

88.Nagakannan P, Islam MI, Conrad M, Eftekharpour E. Cathepsin B is an executioner of ferroptosis. Biochim Biophys Acta Mol Cell Res. 2021;1868:118928. https://doi.org/10.1016/j.bbamcr.2020.118928.

89.Kuang F, Liu J, Li C, Kang R, Tang D. Cathepsin B is a mediator of organelle-specific initiation of ferroptosis. Biochem Biophys Res Commun. 2020;533:1464–9.

90.Pavlovic D, Pekic S, Stojanovic M, Popovic V. Traumatic brain injury: neuropathological, neurocognitive and neurobehavioral sequelae. Pituitary. 2019;22:270–82.

91.Bramlett HM, Dietrich WD. Long-term consequences of traumatic brain injury: current status of potential mechanisms of injury and neurological outcomes. J Neurotrauma. 2015;32:1834–48.

92.Sulhan S, Lyon KA, Shapiro LA, Huang JH. Neuroinflammation and blood–brain barrier disruption following traumatic brain injury: pathophysiology and potential therapeutic targets. J Neurosci Res. 2020;98:19–28.

93.Cash A, Theus MH. Mechanisms of blood–brain barrier dysfunction in traumatic brain injury. Int J Mol Sci. 2020;21. https://doi.org/10.3390/ijms21093344.

94.Mahmoud S, Gharagozloo M, Simard C, Gris D. Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release. Cell. 2019;8. https://doi.org/10.3390/cells8020184.

95.Jha RM, Kochanek PM, Simard JM. Pathophysiology and treatment of cerebral edema in traumatic brain injury. Neuropharmacology. 2019;145:230–46.

96.Donkin JJ, Vink R. Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. Curr Opin Neurol. 2010;23:293–9.

97.Blixt J, Svensson M, Gunnarson E, Wanecek M. Aquaporins and blood–brain barrier permeability in early edema development after traumatic brain injury. Brain Res. 2015;1611:18–28.

98.Papadopoulos MC, Krishna S, Verkman AS. Aquaporin water channels and brain edema. Mt Sinai J Med. 2002;69:242–8.

99.Shah S, Kimberly WT. Today's approach to treating brain swelling in the neuro intensive care unit. Semin Neurol. 2016;36:502–7.

100.Papadopoulos MC, Binder DK, Verkman AS. Enhanced macromolecular diffusion in brain extracellular space in mouse models of vasogenic edema measured by cortical surface photobleaching. FASEB J. 2005;19:425–7.

101.Rosenblum WI. Cytotoxic edema: monitoring its magnitude and contribution to brain swelling. J Neuropathol Exp Neurol. 2007;66:771–8.

102.Milford EM, Reade MC. Resuscitation fluid choices to preserve the endothelial Glycocalyx. Crit Care. 2019;23:77.

103.Zhang C, Chen J, Lu H. Expression of aquaporin-4 and pathological characteristics of brain injury in a rat model of traumatic brain injury. Mol Med Rep. 2015;12:7351–7.

104.Papadopoulos MC, Verkman AS. Aquaporin-4 and brain edema. Pediatr Nephrol. 2007;22:778–84.

105.Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci. 2013;14:265–77.

106.Gong Y, Wu M, Shen J, Tang J, Li J, Xu J, et al. Inhibition of the NKCC1/NF-kappaB Signaling pathway decreases inflammation and improves brain Edema and nerve cell apoptosis in an SBI rat model. Front Mol Neurosci. 2021;14:641993.

107.Cadenas S. ROS and redox signaling in myocardial ischemia–reperfusion injury and cardioprotection. Free Radic Biol Med. 2018;117:76–89.

108.Brini M, Cali T, Ottolini D, Carafoli E. Neuronal calcium signaling: function and dysfunction. Cell Mol Life Sci. 2014;71:2787–814.

109.Rungta RL, Choi HB, Tyson JR, Malik A, Dissing-Olesen L, Lin PJC, et al. The cellular mechanisms of neuronal swelling underlying cytotoxic edema. Cell. 2015;161:610–21.

110.Zhang Z, Wu Y, Yuan S, Zhang P, Zhang J, Li H, et al. Glutathione peroxidase 4 participates in secondary brain injury through mediating ferroptosis in a rat model of intracerebral hemorrhage. Brain Res. 2018;1701:112–25.

111.Tallima H, El Ridi R. Arachidonic acid: physiological roles and potential health benefits - a review. J Adv Res. 2018;11:33–41.

112.Rabinowitz AR, Levin HS. Cognitive sequelae of traumatic brain injury. Psychiatr Clin North Am. 2014;37:1–11.

113.Nakase-Richardson R, Yablon SA, Sherer M. Prospective comparison of acute confusion severity with duration of posttraumatic amnesia in predicting employment outcome after traumatic brain injury. J Neurol Neurosurg Psychiatry. 2007;78:872–6.

114.Arciniegas DB, Held K, Wagner P. Cognitive impairment following traumatic brain injury. Curr Treat Options Neurol. 2002;4:43–57.

115.Barman A, Chatterjee A, Bhide R. Cognitive impairment and rehabilitation strategies after traumatic brain injury. Indian J Psychol Med. 2016;38:172–81.

116.Thompson HJ, Mccormick WC, Kagan SH. Traumatic brain injury in older adults: epidemiology, outcomes, and future implications. J Am Geriatr Soc. 2006;54:1590–5.

117.Walker KR, Tesco G. Molecular mechanisms of cognitive dysfunction following traumatic brain injury. Front Aging Neurosci. 2013;5:29.

118.Ikonomovic MD, Uryu K, Abrahamson EE, Ciallella JR, Trojanowski JQ, Lee VM, et al. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol. 2004;190:192–203.

119.Chen XH, Siman R, Iwata A, Meaney DF, Trojanowski JQ, Smith DH. Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am J Pathol. 2004;165:357–71.

120.Chen XH, Johnson VE, Uryu K, Trojanowski JQ, Smith DH. A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol. 2009;19:214–23.

121.Rui T, Wang H, Li Q, Cheng Y, Gao Y, Fang X, et al. Deletion of ferritin H in neurons counteracts the protective effect of melatonin against traumatic brain injury-induced ferroptosis. J Pineal Res. 2021;70:e12704. https://doi.org/10.1111/jpi.12704.

122.Wang D, Zhang S, Ge X, Yin Z, Li M, Guo M, et al. Mesenchymal stromal cell treatment attenuates repetitive mild traumatic brain injury-induced persistent cognitive deficits by suppressing ferroptosis. J Neuroinflammation. 2022;19:185.

123.Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology. 2000;55:1158–66.

124.Li W, Risacher SL, Mcallister TW, Saykin AJ. Traumatic brain injury and age at onset of cognitive impairment in older adults. J Neurol. 2016;263:1280–5.

125.Yan N, Zhang J. Iron metabolism, Ferroptosis, and the links with Alzheimer's disease. Front Neurosci. 2019;13:1443.

126.Schwarzbold M, Diaz A, Martins ET, Rufino A, Amante LN, Thais ME, et al. Psychiatric disorders and traumatic brain injury. Neuropsychiatr Dis Treat. 2008;4:797–816.

127.Catani M. The anatomy of the human frontal lobe. Handb Clin Neurol. 2019;163:95–122.

128.Rosch KS, Mostofsky S. Development of the frontal lobe. Handb Clin Neurol. 2019;163:351–67.

129.Hidaka BH. Depression as a disease of modernity: explanations for increasing prevalence. J Affect Disord. 2012;140:205–14.

130.Bhatt S, Nagappa AN, Patil CR. Role of oxidative stress in depression. Drug Discov Today. 2020;25:1270–6.

131.Gambini J, Stromsnes K. Oxidative stress and inflammation: from mechanisms to therapeutic approaches. Biomedicine. 2022;10. https://doi.org/10.3390/biomedicines10040753.

132.Silverberg ND, Panenka WJ. Antidepressants for depression after concussion and traumatic brain injury are still best practice. BMC Psychiatry. 2019;19:100.

133.Kreitzer N, Ancona R, McCullumsmith C, Kurowski BG, Foreman B, Ngwenya LB, et al. The effect of antidepressants on depression after traumatic brain injury: a meta-analysis. J Head Trauma Rehabil. 2019;34:E47–54.

134.Kim J, Wessling-Resnick M. Iron and mechanisms of emotional behavior. J Nutr Biochem. 2014;25:1101–7.

135.Phaniendra A, Jestadi DB, Periyasamy L. Free radicals: properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem. 2015;30:11–26.

136.Cao H, Zuo C, Huang Y, Zhu L, Zhao J, Yang Y, et al. Hippocampal proteomic analysis reveals activation of necroptosis and ferroptosis in a mouse model of chronic unpredictable mild stress-induced depression. Behav Brain Res. 2021;407:113261.

137.Dang R, Wang M, Li X, Wang H, Liu L, Wu Q, et al. Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway. J Neuroinflammation. 2022;19:41.

138.Mi Y, Gao X, Xu H, Cui Y, Zhang Y, Gou X. The emerging roles of Ferroptosis in Huntington's disease. NeuroMolecular Med. 2019;21:110–9.

139.Chen J, Marks E, Lai B, Zhang Z, Duce JA, Lam LQ, et al. Iron accumulates in Huntington's disease neurons: protection by deferoxamine. PLoS One. 2013;8:e77023. https://doi.org/10.1371/journal.pone.0077023.

140.Fisher RS, Van Emde BW, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the international league against epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470–2.

141.Verellen RM, Cavazos JE. Posttraumatic epilepsy: an overview. Therapy. 2010;7:527–31.

142.Geronzi U, Lotti F, Grosso S. Oxidative stress in epilepsy. Expert Rev Neurother. 2018;18:427–34.

143.Mori A, Hiramatsu M, Yokoi I, Edamatsu R. Biochemical pathogenesis of posttraumatic epilepsy. Pavlov J Biol Sci. 1990;25:54–62.

144.Zou X, Jiang S, Wu Z, Shi Y, Cai S, Zhu R, et al. Effectiveness of deferoxamine on ferric chloride-induced epilepsy in rats. Brain Res. 2017;1658:25–30.

145.Mueller SG, Trabesinger AH, Boesiger P, Wieser HG. Brain glutathione levels in patients with epilepsy measured by in vivo (1)H-MRS. Neurology. 2001;57:1422–7.

146.Shekh-Ahmad T, Eckel R, Dayalan Naidu S, Higgins M, Yamamoto M, Dinkova-Kostova AT, et al. KEAP1 inhibition is neuroprotective and suppresses the development of epilepsy. Brain. 2018;141:1390–403.

147.Cai Y, Yang Z. Ferroptosis and its role in epilepsy. Front Cell Neurosci. 2021;15:696889.

148.Robledinos-Anton N, Fernandez-Gines R, Manda G, Cuadrado A. Activators and inhibitors of NRF2: a review of their potential for clinical development. Oxidative Med Cell Longev. 2019;2019:9372182.

149.Li F, Wang X, Zhang Z, Zhang X, Gao P. Dexmedetomidine attenuates Neuroinflammatory-induced apoptosis after traumatic brain injury via Nrf2 signaling pathway. Ann Clin Transl Neurol. 2019;6:1825–35.

150.Zeiler FA, Teitelbaum J, West M, Gillman LM. The ketamine effect on ICP in traumatic brain injury. Neurocrit Care. 2014;21:163–73.

151.Liang J, Wu S, Xie W, He H. Ketamine ameliorates oxidative stress-induced apoptosis in experimental traumatic brain injury via the Nrf2 pathway. Drug Des Devel Ther. 2018;12:845–53.

152.Flower O, Hellings S. Sedation in traumatic brain injury. Emerg Med Int. 2012;2012:637171.

153.Itoh T, Satou T, Nishida S, Tsubaki M, Hashimoto S, Ito H. The novel free radical scavenger, edaravone, increases neural stem cell number around the area of damage following rat traumatic brain injury. Neurotox Res. 2009;16:378–89.

154.Fu YS, Chen TH, Weng L, Huang L, Lai D, Weng CF. Pharmacological properties and underlying mechanisms of curcumin and prospects in medicinal potential. Biomed Pharmacother. 2021;141:111888.

155.Dong W, Yang B, Wang L, Li B, Guo X, Zhang M, et al. Curcumin plays neuroprotective roles against traumatic brain injury partly via Nrf2 signaling. Toxicol Appl Pharmacol. 2018;346:28–36.

156.Zhang H, Tang Y, Zhang Y, Zhang S, Qu J, Wang X, et al. Fucoxanthin: a promising medicinal and nutritional ingredient. Evid Based Complement Alternat Med. 2015;2015:1–10.

157.Zhang L, Wang H, Fan Y, Gao Y, Li X, Hu Z, et al. Fucoxanthin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE and Nrf2-autophagy pathways. Sci Rep. 2017;7:46763.

158.Zagorski JW, Turley AE, Freeborn RA, KR VDB, Dover HE, Kardell BR, et al. Differential effects of the Nrf2 activators tBHQ and CDDO-Im on the early events of T-cell activation. Biochem Pharmacol. 2018;147:67–76.

159.Bursley JK, Rockwell CE. Nrf2-dependent and -independent effects of tBHQ in activated murine B cells. Food Chem Toxicol. 2020;145:111595.

160.Crichton RR, Ward RJ, Hider RC. The efficacy of iron Chelators for removing iron from specific brain regions and the pituitary-ironing out the brain. Pharmaceuticals (Basel). 2019;12. https://doi.org/10.3390/ph12030138.

161.Mobarra N, Shanaki M, Ehteram H, Nasiri H, Sahmani M, Saeidi M, et al. A review on iron Chelators in treatment of iron overload syndromes. Int J Hematol Oncol Stem Cell Res, 2016, 10: 239–47.

162.Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, et al. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia. J Med Econ. 2016;19:292–303.

163.Porter JB, Rafique R, Srichairatanakool S, Davis BA, Shah FT, Hair T, et al. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use. Ann N Y Acad Sci. 2005;1054:155–68.

164.Kang H, Han M, Xue J, Baek Y, Chang J, Hu S, et al. Renal clearable nanochelators for iron overload therapy. Nat Commun. 2019;10:5134.

165.Yu J, Yuan Q, Sun YR, Wu X, Du ZY, Li ZQ, et al. Effects of Deferoxamine Mesylate on hematoma and Perihematoma Edema after traumatic intracerebral Hemorrhage. J Neurotrauma. 2017;34:2753–9.

166.Jia H, Liu X, Cao Y, Niu H, Lan Z, Li R, et al. Deferoxamine ameliorates neurological dysfunction by inhibiting ferroptosis and neuroinflammation after traumatic brain injury. Brain Res. 2023;1812:148383.

167.Zhang L, Hu R, Li M, Li F, Meng H, Zhu G, et al. Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury. Neurol Sci. 2013;34:639–45.

168.Kosyakovsky J, Fine JM, Frey WH, 2nd, Hanson LR. Mechanisms of intranasal Deferoxamine in neurodegenerative and neurovascular disease. Pharmaceuticals (Basel). 2021;14. https://doi.org/10.3390/ph14020095.

169.Jamuar SS, Lai AH. Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia. Ther Adv Hematol. 2012;3:299–307.

170.Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17–24.

171.Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci (Elite Ed). 2009;1:161–78.

172.Wongjaikam S, Kumfu S, Khamseekaew J, Sripetchwandee J, Srichairatanakool S, Fucharoen S, et al. Combined iron Chelator and antioxidant exerted greater efficacy on Cardioprotection than monotherapy in iron-overloaded rats. PLoS One. 2016;11:e0159414. https://doi.org/10.1371/journal.pone.0159414.

173.Mettrick K, Hassan K, Lamont I, Reid D. The iron-chelator, N,N'-bis (2-hydroxybenzyl) Ethylenediamine-N,N'-Diacetic acid is an effective Colistin adjunct against clinical strains of biofilm-dwelling Pseudomonas aeruginosa. Antibiotics (Basel). 2020;9. https://doi.org/10.3390/antibiotics9040144.

174.Kang K, Schenkeveld WDC, Biswakarma J, Borowski SC, Hug SJ, Hering JG, et al. Low Fe(II) concentrations catalyze the dissolution of various Fe(III) (hydr)oxide minerals in the presence of diverse ligands and over a broad pH range. Environ Sci Technol. 2019;53:98–107.

175.Khalaf S, Ahmad AS, Chamara K, Dore S. Unique properties associated with the brain penetrant iron Chelator HBED reveal remarkable beneficial effects after brain trauma. J Neurotrauma. 2018;36:43–53.

176.Garrido-Mesa N, Zarzuelo A, Galvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169:337–52.

177.Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC. Minocycline for short-term neuroprotection. Pharmacotherapy. 2006;26:515–21.

178.Zhang L, Xiao H, Yu X, Deng Y. Minocycline attenuates neurological impairment and regulates iron metabolism in a rat model of traumatic brain injury. Arch Biochem Biophys. 2020;682:108302.

179.Hatcher HC, Singh RN, Torti FM, Torti SV. Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem. 2009;1:1643–70.

180.Ramadhan MIA, Sitanaya SN, Hakim AHW, Ramli Y. The Role of Iron-Chelating Therapy in Improving Neurological Outcome in Patients with Intracerebral Hemorrhage: Evidence-Based Case Report, Vol. 59. Medicina (Kaunas), 2023. https://doi.org/10.3390/medicina59030453.

181.Miotto G, Rossetto M, Di Paolo ML, et al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 2020;28:101328.

182.Liu P, Feng Y, Li H, Chen X, Wang G, Xu S, et al. Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting via inhibiting ferroptosis. Cell Mol Biol Lett. 2020;25:10.

183.Horwath MC, Bell-Horwath TR, Lescano V, Krishnan K, Merino EJ, Deepe GS, Jr. Antifungal activity of the lipophilic antioxidant Ferrostatin-1. Chembiochem. 2017;18:2069–78.

184.Jin Y, Lin Y, Feng JF, Jia F, Gao GY, Jiang JY. Moderate hypothermia significantly decreases hippocampal cell death involving autophagy pathway after moderate traumatic brain injury. J Neurotrauma. 2015;32:1090–100.

185.Abdalkader M, Lampinen R, Kanninen KM, Malm TM, Liddell JR. Targeting Nrf2 to suppress Ferroptosis and mitochondrial dysfunction in neurodegeneration. Front Neurosci. 2018;12:466.

186.Fan BY, Pang YL, Li WX, Zhao CX, Zhang Y, Wang X, et al. Liproxstatin-1 is an effective inhibitor of oligodendrocyte ferroptosis induced by inhibition of glutathione peroxidase 4. Neural Regen Res. 2021;16:561–6.

187.Feng Y, Madungwe NB, Imam Aliagan AD, Tombo N, Bopassa JC. Liproxstatin-1 protects the mouse myocardium against ischemia/reperfusion injury by decreasing VDAC1 levels and restoring GPX4 levels. Biochem Biophys Res Commun. 2019;520:606–11.

188.Wu H, Lu D, Jiang H, Xiong Y, Qu C, Li B, et al. Increase in phosphorylation of Akt and its downstream signaling targets and suppression of apoptosis by simvastatin after traumatic brain injury. J Neurosurg. 2008;109:691–8.

189.Lu D, Goussev A, Chen J, Pannu P, Li Y, Mahmood A, et al. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma. 2004;21:21–32.

190.Zhao Q, Chen XY, Martin C. Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants. Sci Bull (Beijing). 2016;61:1391–8.

191.Xie Y, Song X, Sun X, Huang J, Zhong M, Lotze MT, et al. Identification of baicalein as a ferroptosis inhibitor by natural product library screening. Biochem Biophys Res Commun. 2016;473:775–80.

192.Patwardhan RS, Sharma D, Thoh M, Checker R, Sandur SK. Baicalein exhibits anti-inflammatory effects via inhibition of NF-kappaB transactivation. Biochem Pharmacol. 2016;108:75–89.

193.Tuli HS, Aggarwal V, Kaur J, Aggarwal D, Parashar G, Parashar NC, et al. Baicalein: a metabolite with promising antineoplastic activity. Life Sci. 2020;259:118183. https://doi.org/10.1016/j.lfs.2020.118183.

194.Li M, Meng Z, Yu S, Li J, Wang Y, Yang W, et al. Baicalein ameliorates cerebral ischemia–reperfusion injury by inhibiting ferroptosis by regulating GPX4/ACSL4/ACSL3 axis. Chem Biol Interact. 2022;366:110137. https://doi.org/10.1016/j.cbi.2022.110137.

195.Liu C, Wu J, Gu J, Xiong Z, Wang F, Wang J, et al. Baicalein improves cognitive deficits induced by chronic cerebral hypoperfusion in rats. Pharmacol Biochem Behav. 2007;86:423–30.

196.Gu XH, Xu LJ, Liu ZQ, Wei B, Yang YJ, Xu GG, et al. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease. Behav Brain Res. 2016;311:309–21.

197.Deschamps JD, Kenyon VA, Holman TR. Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg Med Chem. 2006;14:4295–301.

198.Tordjman S, Chokron S, Delorme R, Charrier A, Bellissant E, Jaafari N, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15:434–43.

199.Karaaslan C, Suzen S. Antioxidant properties of melatonin and its potential action in diseases. Curr Top Med Chem. 2015;15:894–903.

200.Qin W, Li J, Zhu R, Gao S, Fan J, Xia M, et al. Melatonin protects blood–brain barrier integrity and permeability by inhibiting matrix metalloproteinase-9 via the NOTCH3/NF-kappaB pathway. Aging (Albany NY). 2019;11:11391–415.

201.Blum B, Kaushal S, Khan S, Kim JH, Alvarez Villalba CL. Melatonin in traumatic brain injury and cognition. Cureus. 2021;13:e17776.

202.Wanet A, Tacheny A, Arnould T, Renard P. miR-212/132 expression and functions: within and beyond the neuronal compartment. Nucleic Acids Res. 2012;40:4742–53.

203.Wang W, Bian H, Li F, Li X, Zhang D, Sun S, et al. HBeAg induces the expression of macrophage miR-155 to accelerate liver injury via promoting production of inflammatory cytokines. Cell Mol Life Sci. 2018;75:2627–41.

204.Inamura K, Ishikawa Y. MicroRNA in lung cancer: novel biomarkers and potential tools for treatment. J Clin Med. 2016;5. https://doi.org/10.3390/jcm5030036.

205.Atif H, Hicks SD. A review of MicroRNA biomarkers in traumatic brain injury. J Exp Neurosci. 2019;13:1179069519832286.

206.Johnson WD, Griswold DP. Traumatic brain injury: a global challenge. Lancet Neurol. 2017;16:949–50.

207.Ray SK, Dixon CE, Banik NL. Molecular mechanisms in the pathogenesis of traumatic brain injury. Histol Histopathol. 2002;17:1137–52.

208.Wu Q, Xu LJ, Jia BH, Peng YL, Li CJ. Effects of positive end-expiratory pressure setting of mechanical ventilation guided by esophageal pressure in the treatment of patients with traumatic craniocerebral injury combined with acute respiratory distress syndrome. Zhonghua Shao Shang Za Zhi. 2021;37:446–52.

209.Conrad M, Kagan VE, Bayir H, Pagnussat GC, Head B, Traber MG, et al. Regulation of lipid peroxidation and ferroptosis in diverse species. Genes Dev. 2018;32:602–19.

210.Wei Z, Xie Y, Wei M, Zhao H, Ren K, Feng Q, et al. New insights in ferroptosis: potential therapeutic targets for the treatment of ischemic stroke. Front Pharmacol. 2022;13:1020918.

211.Geng Z, Guo Z, Guo R, Ye R, Zhu W, Yan B. Ferroptosis and traumatic brain injury. Brain Res Bull. 2021;172:212–9.

212.Maas AIR, Menon DK, Manley GT, Abrams M, Akerlund C, Andelic N, et al. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol. 2022;21:1004–60.

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Luminol-conjugated cyclodextrin biological nanoparticles for the treatment of severe burn-induced intestinal barrier disruption

Regulated necrosis pathways: a potential target for ischemic stroke

Cellular and molecular mechanisms in vascular repair after traumatic brain injury: a narrative review

MicroRNAs in septic acute kidney injury

Gut, metabolism and nutritional Support for COVID-19: Experiences from China